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ABSTRACT
Objectives: To evaluate the incidence and dose-dependency of mitoxantrone (MTX)-associated
acute myelocytic leukemia (AML) in the network of Italian multiple sclerosis (MS) clinics.
Methods:We performed a multicenter retrospective cohort study of patients treated with MTX in
MS centers under the Italian national health care system between 1998 and 2008. Demo-
graphic, disease, treatment, and follow-up information were collected using hospital records.
Results: Data were available for 3,220 patients (63% women) from 40 Italian centers. Follow-up
(meanSD)was4929months (range12–140months).We observed30cases of AML (incidence
0.93% [95%confidence interval 0.60%–1.26%]). Themean cumulative dosewas higher in patients
with AML (78 vs65mg/m2, p0.028). Themedian interval from the start of therapy toAMLdiagno-
sis was longer than expected at 33months (range 13–84months); 8 patients (27%) developed AML
4 years or more after the first MTX infusion. The rate of mortality associatedwith AMLwas 37%.
Conclusions: This higher than expected risk of AML and related mortality requires that treatment
decisionsmust bemade jointly betweenclinicians andpatientswhounderstand their prognosis, treat-
ment options, and treatment-related risks. The now large exposed MS population must be monitored
for hematologic abnormalities for at least 6 years from the end of therapy, to ensure the rapid actions
needed for early diagnosis and treatment of AML. Neurology® 2011;77:1887–1895
GLOSSARY
AML  acute myelocytic leukemia; APL  acute promyelocytic leukemia; CI  confidence interval; MS  multiple sclerosis;
MTXmitoxantrone; PML progressive multifocal leukoencephalopathy; ROC receiver operating characteristic.
Mitoxantrone (MTX) is an anthracenedione derivative that intercalates into DNA, poisons
topoisomerase II, and causes strand breaks that can result in chromosomal translocations.1
Though originally developed as an antineoplastic, its immunosuppressive properties proved
efficacious in managing multiple sclerosis (MS).2,3
Scattered reports of secondary leukemia led to restrictions on cumulative dose and a warning
to monitor for adverse events.4–11 In oncology, the use of topoisomerase II inhibitors had
already been associated with a higher risk of secondary leukemia.12 However, oncology patients
are often exposed to more genotoxic stress than patients treated for MS and an early retrospec-
tive study of MTX in MS had revealed a low incidence of therapy-related acute myelocytic
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leukemia (AML).13 Subsequent case and series
reports have indicated that the incidence may
be considerably higher.14–21 The Therapeutics
and Technology Assessment Subcommittee of
the American Academy of Neurology recently
conducted a systematic review of the evidence
on the efficacy and safety of MTX, conclud-
ing that the incidence of treatment-related
AML appears to be higher than previously
thought, but that “comprehensive postmar-
keting surveillance data are lacking.”22 The
entity of risk and the relationship between ex-
posure and risk remain uncertain.
We have sought to resolve these questions
by identifying a large cohort of patients with
MS with well-defined exposure to MTX and
determining how many of them had devel-
oped AML over time.
METHODS Study design. In this retrospective cohort
study, we collected data on a majority of Italian patients with
MS treated with at least one infusion of MTX and observed for
at least 1 year between 1998 and 2008. In Italy, patients with
MS receive treatment within the network of MS centers regis-
tered with the Italian Health Authorities. A letter describing the
study was sent to all MS centers in June 2007 and centers with
experience treating at least 10 patients with MTX were invited to
participate.
Participating centers were urged to identify and collect data
on all patients treated during the study period. The following
data were retrieved through review of the clinical databases at
each center: demographic data, disease onset and clinical course,
first and most recent MTX administrations, dosage, number of
infusions, cumulative dose, and duration of follow-up. Detailed
information on MS, cytogenetics, and previous therapies were
requested for patients who developed leukemia.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the institutional review
board of the San Raffaele Institute, Milan, who waived the re-
quirement for informed consent due to the nature of the study.
Statistical analyses. The incidence rate of AML in patients
with MS treated with MTX, as well as the incidence rate of death
for patients who had AML, were determined using Poisson dis-
tribution. The duration of follow-up was calculated from the
initiation of therapy to the last patient contact.
To identify factors that influence the risk of AML we ana-
lyzed differences in the occurrence of potential risk factors be-
tween patients who developed acute leukemia and patients who
did not. We applied the Mann-Whitney U test for continuous
variables and the Fisher exact test for categorical data. The results
were described as mean and SD, median and interquartile range,
or counts with percentages, where appropriate. Possible correla-
tions between the diagnosis of AML and the cumulative dose of
MTX or the interval from last infusion were assessed using
Spearman rank correlation coefficients.
Variables that were found to be associated significantly with
AML in univariate analyses were analyzed by multivariate Pois-
son regression, adjusting for potential confounding factors.
These results were expressed as crude and adjusted rate ratios
with 95% confidence intervals. To define the cutoff point of
higher AML risk with cumulative dose of MTX, sensitivity and
specificity were calculated as receiver operating characteristic
(ROC) curves. The optimum was defined using the criteria of a
balanced sensitivity and specificity and confirmed by Poisson
regression with relative risk.
The study was approved by the Ethics Committee of the
Coordinating Center (S. Raffaele Institute, Milan, Italy). Statis-
Table 1 Demographic and clinical patient characteristics
MV, n (%) No. ALL No. AML () No. AML () p Value
Patients — 3,220 3,190 30 30
Female, n (%) — 3,220 2,044 (63) 3,190 2,028 (64) 30 16 (53) 0.246
Age, y, mean (SD) 69 (2.1) 3,151 44.2 (10.4) 3,121 44.2 (10.3) 30 44.0 (11.6) 0.748
MS course, n (%) 57 (1.8) 3,163 3,133 30 0.152
PP 186 (6) 184 (6) 2 (7)
RR 1,411 (45) 1,393 (44) 18 (60)
SP 1,566 (49) 1,556 (50) 10 (33)
No. of cycles, n (%) 55 (1.7) 3,165 3,135 30 0.280
Min–max 1–24 1–24 1–16
Median (IQR) 7 (5–10) 7 (5–10) 8.5 (6–11)
Duration of treatment, mo, n (%) 36 (1.1) 3,184 3,154 30 0.437
Min–max 0.03–120.8 0.03–120.8 0.03–47.0
Median (IQR) 14.7 (7–24) 14.7 (7–24) 17.0 (7–26)
Cumulative dose, mg/m2, n (%) 185 (6) 3,035 3,005 30 0.028
Min–max 5–144 5–144 12–130
Median (IQR) 60 (40–90) 60 (40–90) 72 (60–108)
Abbreviations: ALL  acute lymphoblastic leukemia; AML  acute myelocytic leukemia; IQR  interquartile range; MS multiple sclerosis; MV missing
value; PP primary progressive; RR relapsing-remitting; SP secondary progressive.
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tical analyses were performed by M.P. using Stata statistical soft-
ware, version 10 (StataCorp, College Station, TX).
RESULTS Forty centers, located throughout Italy,
participated in this study. They represent 85%–90%
of all patients treated with MTX in Italy during the
study period.
By 2008, the 19 major Italian MS centers had
managed approximately 30,000 patients with MS,
26,000 of whom were seen in the 16 major centers
participating in this study (2 centers had not treated
at least 10 patients and one had not prospectively
collected data on all patients, making it impossible to
determine the exact number of patients treated).
We collected data on 3,220 patients with MS
treated with MTX; the 16 major MS centers contrib-
uted a median of 113 patients (range 63–539). The
main clinical and demographic characteristics of the
cohort are summarized in table 1.
Figure 1 Exposure to MTX treatment
(A) Distribution of the mitoxantrone (MTX) infusion number (mean number of infusions  7.6). (B) Distribution of single
patient cumulative dose of MTX (patients’ mean cumulative dose 64.8 mg/m2).
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Various dosage regimens were used, with MTX
administered about monthly in 940 patients, every 2
months in 1,280 patients, every 3 months in 684
patients, and at intervals of 4 or more months in 183
patients. A regular administration pattern was not
observed in 133 patients. The mean number of MTX
administrations was 7.6 and the mean cumulative
dose was 64.8 mg/m2 (figure 1, A and B). Sixty-two
percent of patients received a cumulative dose be-
tween 30 and 89 mg/m2. The cumulative doses ad-
ministered to patients who developed AML are
presented in table 2. Follow-up (mean  SD) was
48.3  28.3 months (range 12–140); only 779 pa-
tients were observed for less than 24 months.
We observed 30 cases of AML (table 2). Acute
promyelocytic leukemia (APL) was the most fre-
quently reported AML subtype (19 cases), represent-
ing 76% of the patients with defined subtypes. One
case each of chronic myeloid leukemia and acute
lymphoblastic leukemia were recorded but not in-
cluded in evaluations because they are not considered
to be treatment-related. The incidence of AML was
0.93% (95% confidence interval [CI] 0.60%–
1.26%), which represents a global risk of 1 case per
Table 2 Demographic and clinical characteristics of the patients who developed AML
Sex MS
Cumulative
dose, mg/m2
Age at start of
MTX therapy, y
Interval from start of
therapy to AML
diagnosis, mo Type of AMLa
Leukemia outcome
so far
M RR 12 24 13 M3 Remission
F SP 22.5 56 36 M3 Remission
F RR 24 28 28 M3 Remission
F RR 30 46 16 M3 Remission
M SP 45 30 36 M3 Remission
F SP 48 50 63 Not stated Death
M RR 50 60 39 Not stated Death
F RR 60 43 35 M3 Death
M SP 60 35 56 M3 Death
F RR 60 23 25 M4 Remission
M SP 60 44 24 Not stated Death
F SP 60 35 39 M3 Remission
M PP 71 37 20 M3 Remission
M SP 72 48 31 M3 Remission
F PP 72 61 20 M3 Death
F RR 72 28 84 M3 Remission
M RR 90 25 47 M3 Death
F RR 95 33 25 M4 Remission
M SP 96 52 31 Not stated Death
M RR 96 32 26 Not stated Death
F RR 100 34 35 M3 Remission
F RR 100 24 32 M3 Remission
F RR 108 27 36 M2 Death
M RR 110 37 22 M3 Remission
F RR 110 59 68 M5 Remission
M SP 110 58 45 M3 Remission
M RR 120 46 28 M3 Remission
M SP 120 58 49 M7 Death
F RR 130 55 50 M3 Remission
F RR 130 47 40 M4 Remission
Abbreviations: AML acutemyelocytic leukemia; MSmultiple sclerosis; MTXmitoxantrone; PP primary progressive;
RR relapsing-remitting; SP secondary progressive.
a AML subtypes according to the French-American-British Classification (M2 acute myeloblastic leukemia; M3 acute pro-
myelocytic leukemia; M4 acute myelomonocytic leukemia; M5 acute monoblastic leukemia; M7 acute megakaryoblastic
leukemia).
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107 MTX-treated patients. We estimated an AML
incidence rate of 0.19 (95% CI 0.14–0.28) per
1,000 person-months. Four of the patients who de-
veloped AML had been treated previously with im-
munosuppressive drugs (3 with azathioprine and 1
with cyclophosphamide). All others had received
first-line immunomodulating therapy. The median
interval from the start of MTX therapy to the diag-
nosis of AML was 33.3 months (range 13.3–84.2
months; interquartile range 24.6–40.3).
Patients who developed AML had received a
higher mean cumulative dose of MTX than patients
who did not (78 vs 65 mg/m2, p  0.028), suggest-
ing a relationship between cumulative dose and the
development of AML (figure 2). Using cumulative
dose as the exposure factor and adjusting for the du-
ration of treatment and number of cycles, we ob-
served a rate ratio of 1.03 (95% CI 1.01–1.06, p 
0.005). In other words, there was a 3% increase in
the risk of AML for every one unit increase in cumu-
lative dose. We then categorized cumulative dose us-
ing quartiles based on the 25th, 50th, and 75th
percentiles of the cumulative doses received by pa-
tients who developed AML and calculated the crude
and adjusted rate ratio for each category. An excess
risk of AML was observed for all 3 dose categories
analyzed (table 3). The rate ratio adjusted for dura-
tion of treatment and number of cycles was higher,
but the level of significance was similar. We observed
a higher risk of AML (rate ratio  4.89, p  0.004)
in patients who had a cumulative MTX dose 108
mg/m2. Using ROC analysis, we identified a cumu-
lative dose of 90 mg/m2 as the cutoff point best asso-
ciated with higher AML risk (sensitivity 47%,
specificity 75%). The Poisson regression demon-
strated that patients with cumulative doses higher
than 90 mg/m2 had a risk ratio of 3.44 (95% CI
0.92–3.87, p  0.014).
No significant difference was observed between
MTX-treated patients who developed or did not de-
velop AML regarding gender, age, disease course,
number of infusions, individual infusion dose, or du-
ration of treatment.
At this writing, 11 of the 30 patients who devel-
oped AML have died (mortality rate 36.7%) with a
corresponding mortality incidence rate of 1.09 (95%
CI 0.58–2.02) per 100 cases of AML-month. Six
patients (20%) died before any diagnostic workup or
induction therapy. The median survival time was 31
months. We estimated an incidence rate of death due
to AML of 0.07 (95% CI 0.04–0.13) per 1,000
person-months treated with MTX. No significant
difference was observed in leukemia outcome when
patients were analyzed on the basis of cumulative
MTX dose (p  0.793), number of infusions (p 
0.229), duration of MTX treatment (p  0.401),
age (p  0.254), or AML subtype (p  0.190).
DISCUSSION Our main finding is a high incidence
of AML in Italian patients with MS treated with
MTX. Our results strongly support that the risk of
AML in MTX-treated patients with MS is similar to
that associated with the use of topoisomerase II in-
hibitors in the oncology setting.23
The high incidence of AML observed in our
MTX-treated cohort of patients is significantly
higher than the average incidence (about 1:1,000)
observed in the Italian general population with age
lower than 64 years (Italian Network of Cancer Reg-
istries, 1998–2002). This finding contrasts with the
absence of treatment-related leukemia in the early
studies that supported the regulatory approval of
MTX for this indication,2,3 however, this may be due
to the relatively small group sizes and short durations
of these studies, which were directed primarily at es-
tablishing efficacy and not adequately powered to de-
tect rare adverse drug reactions. Subsequently, much
Figure 2 Box plot of cumulative dose of mitoxantrone (MTX) for patients with
() and without () acute myelocytic leukemia (AML)
Table 3 Crude and adjusted rate ratio of AML
cases in patients with MS
Cumulative dose
Unadjusted RR
(95%CI)a
Adjusted RR
(95%CI)b
>60mg/m2 1.55 (0.69–3.48) 2.30 (0.86–6.17)
>72mg/m2 1.40 (0.68–2.88) 2.16 (0.83–5.65)
>108mg/m2 2.33 (1.04–5.24) 4.89 (1.64–14.63)
Abbreviations: AML acute myelocytic leukemia; CI con-
fidence interval; MSmultiple sclerosis; RR rate ratio.
a Poisson regression model.
b Poisson regression model adjusted for duration of treat-
ment and number of cycles.
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higher cumulative incidences were found in a num-
ber of relatively small case series.19,20 Our findings
also contrast with those of a recently concluded phase
IV postmarketing surveillance study.24
Estimates of the incidence of treatment-related
AML after therapy with MTX vary considerably. A
meta-analysis of data from 15 large case series recent
showed a 3-year MTX-related leukemia incidence of
0.33% in 5,472 MTX-treated patients with MS.20
Although lower than our finding, their estimate of
the risk of acute leukemia (1:333) represents a signif-
icant increase over the risk for the general popula-
tion. Meanwhile, a long-term prospective study
observed 230 MTX-treated patients with MS for a
mean of nearly 5 years from start of therapy, identify-
ing 5 cases of AML and an incidence of 2.2%.19 Our
data, obtained after a mean follow-up of 4 years from
the start of therapy, indicate a risk intermediate be-
tween these reports and in agreement with an esti-
mated incidence of 0.81% from a recent analysis of
all published data for which a denominator was avail-
able, regardless of length of follow-up.22 At least part
of the difference in incidence among these studies
may be attributed to variation in the length of observa-
tion; however, contributions from different treatment
regimens (e.g., combination with methylprednisolone),
and population-level differences in genetic factors influ-
encing DNA repair, drug metabolism, or susceptibility
to AML itself, must be taken into account.25
While we did not identify independent patient
characteristics that affected AML risk, it is important
to point out that we did not collect data on health
behaviors, lifestyle, or comorbidities. For example,
smoking is a weak risk factor for AML that causes a
30% increase in AML risk (smokers vs lifelong non-
smokers).26 When we designed this study the inci-
dence of AML in Italian patients treated with MTX
was not known and we decided to focus on “essen-
tial” data addressing this question. We sought to re-
duce the collection burden on participating centers
in hope of obtaining maximum participation in the
absence of financial support, albeit at a cost of less
detailed information on individual patients. A case-
control study on all MTX-treated patients with MS
should be planned to investigate cofactors potentially
able to influence cancer risk.
Data from several large MS cohorts reveal a re-
duction in the risk of several cancers in untreated
patients with MS.27,28 Moreover, none of these large
population-based studies report a significant increase
in “hematopoietic or lymphatic” malignancies
among patients with MS. The cumulative risk of
AML in the Italian general population below the age
of 64 years is approximately 9 times less than the
incidence we observed in MTX-treated patients.
This difference would be even greater if, for instance,
heightened immune surveillance in untreated pa-
tients with MS resulted in a lower incidence of AML.
The first reported MTX-related acute leukemia
manifested after 5 years,5 and, while this has been
described as an outlier,22 our results suggest that late
onset of AML may be more frequent than previously
thought. Therefore monitoring for hematologic ab-
normalities related to acute leukemia should con-
tinue for 6 years from the end of MTX exposure. At
this writing, only about half of our patients have
been observed for 5 years and additional cases are
likely to develop.
The second major question was whether the risk
of developing AML is dose-dependent. Our findings
indicate that the frequency of AML increases pro-
gressively in patients who received higher cumulative
doses of MTX, confirming a recent report.20 This has
important implications for therapy and, although it
is not possible to establish a safe cumulative dose,
based on current information, a reasonable cumula-
tive dose might be 30–60 mg/m2 administered as
part of a therapeutic strategy to reduce exposure to
MTX.
One such strategy is a sequential treatment regi-
men that employs short-term MTX induction ther-
apy followed by maintenance therapy with a better
tolerated immunomodulating therapy. In theory,
this approach takes advantage of a powerful immu-
nosuppressant to “reset” the immune system, result-
ing in the replacement of proinflammatory cells with
anti-inflammatory cells.29 Initial evaluations have
shown that this strategy is efficacious,29 but the num-
ber of patients treated to date do not permit a rigor-
ous analysis of safety. Based on available data, a low
MTX cumulative dose would be expected to have a
lower, but ever-present risk of therapy-related leukemia
and therefore still warrant long-term surveillance.
The impact of our findings on clinical practice
should be to require a careful evaluation of treatment
options by clinicians together with each candidate
for therapy, in light of prognostic clinical and MRI
parameters. The potential benefits of MTX treat-
ment in preventing progressive irreversible disability
from MS must be balanced against the risk of
treatment-related mortality from cardiotoxicity and
secondary leukemia. We should consider not only
the higher incidence of therapy-related leukemia
with MTX, but also the mortality rate associated
with it. Alternative therapies and their associated
risks should also be considered. The anti-integrin 4
monoclonal natalizumab, also approved for this indi-
cation, has an associated risk of mortality from pro-
gressive multifocal leukoencephalopathy (PML) of
0.3 per 1,000 patients.30
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The attitudes of a large group of patients with MS
toward assuming the risk of life-threatening
treatment-related effects in return for better MS out-
comes were assessed recently with a survey question-
naire.31 It was revealed that patient concerns center
mainly on mortality from therapy-related adverse
events, rather than the adverse events themselves.
It is also necessary that the estimated tens of thou-
sands of patients exposed to MTX over the past 6
years be closely monitored for adverse hematologic
events. AML usually progresses rapidly and may be
fatal within days or weeks if untreated. A serious
warning comes from the fact that 6 out of 11 patients
died before any initial workup or induction therapy.
Early detection of hematologic abnormalities related
to an incipient acute leukemia is crucial to prevent-
ing dramatic and fatal evolution of the disease. Sus-
pected leukemia should be managed as a medical
emergency. Current treatment strategies provide ex-
cellent therapeutic results in the management of
AML,32 particularly APL.33
The retrospective manner in which our data were
collected could represent a limitation, since an inde-
finable number of patients who received MTX may
not have been included in the denominator; how-
ever, we believe that this had a limited impact on our
analysis. We would argue that the well-organized
network of MS centers under the Italian National
Health System, the systematic recording of informa-
tion in databases, and the requirement that patients
present at registered centers for treatment and
follow-up has allowed us to identify nearly 90% of
the exposed population. We must also keep in mind
that, at this writing, only about half of the Italian
patients have had 5 years of follow-up and additional
patients are likely to develop AML in the coming
months or years. Likewise, this close association of
Italian MS centers and the severity of AML make it
unlikely that a case of AML would go unreported.
On the contrary, the published prospective studies
have had10% loss of patients from death or loss to
follow-up, leading to the possibility that patients
who developed AML were not identified.24,34
Finally, 10 years are usually necessary to define
the efficacy and the short-term side effects of a new
drug before it reaches the market, but it has taken
another 10 years of comprehensive postmarketing
surveillance to appreciate the true incidence of severe
and life-threatening side effects related to MTX. The
MTX “lesson” must represent a warning for emerg-
ing therapies that comprehensive, thorough, and
long-term postmarketing surveillance must be car-
ried out in each country and lead to periodic reanal-
ysis of the global risk/benefit ratio. In the future, only
the combined effort and collaboration of pharmaceu-
tical companies, drug regulatory agencies, and clini-
cal practitioners will be able to ensure timely
solutions. Nevertheless it could be that the latter are
best suited, if not the best equipped, to be entrusted
with the task of active long-term surveillance in the
real-world setting, with the goal of moving toward an
innovative postmarketing drug safety model.35 In-
vestment in informatics infrastructure and systematic
data collection systems that integrate also informa-
tion from national health care databases and census
information would help to overcome the limitations
of voluntary reporting and could be one solution to
this challenge.
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